Skip to content

Study · Observational study · n = 187 · 2005

5 results

[Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency].

Gusev EI, Skvortsova VI, Chukanova EI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2005Cited by 9 (Europe PMC)

PMID15792140 (opens in a new tab)PepBankPUB-15792140
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with cerebrovascular insufficiency, semax treatment resulted in significant clinical improvement.

    In plain wordsIn patients with cerebrovascular insufficiency, semax treatment was linked to significant clinical improvement.

    Peptide
    Semax
    Outcome
    IncreaseClinical improvement in cerebrovascular insufficiency
    Study

    n = 187

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semax treatment resulted in significant clinical improvement
    1 context sentence
    Summary · context
    One hundred and eighty-seven patients with different stages of cerebrovascular insufficiency (CI) have been examined.
  2. 02HumanObservational studyEfficacy outcome

    In patients with cerebrovascular insufficiency, semax treatment stabilized disease progression.

    In plain wordsIn patients with cerebrovascular insufficiency, semax treatment was linked to a stable disease course.

    Peptide
    Semax
    Outcome
    DecreaseDisease progression
    Study

    n = 187

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semax treatment resulted in significant clinical improvement, stabilization of the disease progress and reduced a risk of stroke and transitory ischemic attacks in the disease course.
    1 context sentence
    Summary · context
    One hundred and eighty-seven patients with different stages of cerebrovascular insufficiency (CI) have been examined.
  3. 03HumanObservational studyEfficacy outcome

    In patients with cerebrovascular insufficiency, semax treatment reduced the risk of stroke and transitory ischemic attacks during the disease course.

    In plain wordsIn patients with cerebrovascular insufficiency, semax treatment was linked to a lower risk of stroke and mini-strokes.

    Peptide
    Semax
    Outcome
    DecreaseRisk of stroke and transitory ischemic attacks
    Study

    n = 187

    Outcome group
    Cardiovascular events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    reduced a risk of stroke and transitory ischemic attacks in the disease course.
    1 context sentence
    Summary · context
    One hundred and eighty-seven patients with different stages of cerebrovascular insufficiency (CI) have been examined.
  4. 04HumanObservational studySafety outcome

    In patients with cerebrovascular insufficiency, semax was featured by a minor percent of side effects.

    In plain wordsIn patients with cerebrovascular insufficiency, only a small share had side effects with semax.

    Peptide
    Semax
    Outcome
    Not applicableSide effects
    Study

    n = 187

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The drug is featured by minor percent of side-effects
    1 context sentence
    Summary · context
    One hundred and eighty-seven patients with different stages of cerebrovascular insufficiency (CI) have been examined.
  5. 05HumanObservational studySafety outcome

    In patients with cerebrovascular insufficiency, semax was well tolerated, including by patients of older age groups.

    In plain wordsIn patients with cerebrovascular insufficiency, semax was well tolerated, also by older patients.

    Peptide
    Semax
    Outcome
    Not applicableTolerability
    Study

    n = 187

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    well tolerated by patients, including those of older age groups.
    1 context sentence
    Summary · context
    One hundred and eighty-seven patients with different stages of cerebrovascular insufficiency (CI) have been examined.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.